Tumor single sample homologous recombination defect detection method based on high-throughput sequencing
By constructing a normal population database and tumor single-sample high-throughput sequencing data, we simulate somatic cell results, and solve the problem of redundancy and high cost of tumor single-sample HRD evaluation, and achieve accurate HRD status assessment and drug selection basis provision .
Patent Information
- Application Number
- CN202410985853.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-22
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-07-22
AI Technical Summary
Existing high-throughput sequencing techniques have problems such as data redundancy, high cost, and difficulty in obtaining control samples when evaluating homologous recombination defects (HRD) status in tumor single samples, resulting in inaccurate or inability to perform HRD evaluation.
By constructing a database of SNP and copy number variations of normal populations, combining high-throughput sequencing data of single-sample tumors, the results of SNP and copy number variations of somatic cells were simulated, and homologous recombination defects were detected to achieve evaluation of HRD status.
This method can accurately evaluate the HRD status of a single tumor sample without the need for a control sample, reduce costs, simplify the process, and provide a basis for drug selection. It is especially suitable for patients who cannot obtain a control sample.
Smart Images

Figure HDA0004958681180000011 
Figure HDA0004958681180000012 
Figure HDA0004958681180000013
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of bioinformatics and high-throughput sequencing, and in particular relates to a method for detecting homologous recombination defects in a single tumor sample based on high-throughput sequencing. Background Art
[0002] The genome of human cells is formed by the winding of DNA double helix. When cells divide, the double-stranded DNA unwinds and serves as the template strand to replicate the daughter strand. Therefore, the accuracy of DNA replication is very important for survival and reproduction. Accurate replication is not only the basis for stable inheritance of species, but also the guarantee for maintaining genome integrity. It is a necessary condition for cells to maintain basic growth and perform normal functions. However, DNA replication is not 100% accurate, and its mismatch probability is about 10 -10 , and environmental factors, such as radiation, ultraviolet light, chemical mutagens, etc., can also cause errors or damage in the DNA sequence. When a single-strand mismatch or damage occurs in DNA, there are three main repair methods: base patch repair, nucleotide patch repair, and mismatch repair. The parental chain is mainly used as a template to repair the damaged area. When a double-strand mismatch or damage occurs in DNA, there are two repair methods: homologous recombination repair and non-homologous end joining repair. Non-homologous end joining repair directly links the two broken parts. Several bases may be randomly introduced and removed during the repair process. It is a high-efficiency, low-accuracy repair method. Homologous recombination repair uses the homologous sequence of the uninjured sister chromatid as a repair template. It is a low-efficiency, high-accuracy repair method.
[0003] When homologous recombination repair is dysfunctional, that is, homologous recombination defect HRD occurs, double-strand damage is mainly repaired by non-homologous recombination, which will lead to errors such as insertion, deletion, and copy number abnormalities of DNA fragments. Over time, errors continue to accumulate, leading to cell apoptosis or transformation into cancer cells. HRD occurs in different tumors, the most common of which include ovarian cancer, bladder cancer, breast cancer, endometrial cancer, prostate cancer, and pancreatic cancer. Currently known causes of HRD include: BRCA1 / 2 gene mutations, BRCA1 promoter methylation, other gene mutations in the homologous recombination repair pathway, and other factors that lead to downregulation of BRCA gene expression.
[0004] Since HRD is the result of multiple reasons, it is difficult to fully assess the HRD status by only detecting mutations in genes on the homologous repair recombination pathway. Studies have found that when cells develop HRD, they rely too much on non-homologous recombination for repair, and the introduction of insertions, deletions, and copy number abnormalities leads to specific traces on the genome, called genomic scars. There are three forms of genomic scars: loss of heterozygosity, large fragment migration, and telomeric allele imbalance. The combination of these three indicators can be used to determine the HRD status of the genome. Tumor patients with high HRD status are highly sensitive to platinum drugs and PARP inhibitors that cause DNA breaks, especially ovarian cancer patients. HRD has become one of the important markers related to the treatment of ovarian cancer with PARP inhibitors.
[0005] In the early days, people used SNP chip technology to evaluate HRD status, but it was expensive. With the development of second-generation sequencing NGS, the sequencing costs of whole genome sequencing WGS and whole exome sequencing WES have gradually decreased, and HRD evaluation has gradually shifted to the NGS platform. However, there are defects in using WGS and WES to evaluate HRD status. WGS evaluates HRD accurately, but the data is redundant and the cost is too high. WES is cheaper, but WES does not evenly cover the entire genome, so there are deviations in judging HRD. At present, judging HRD status requires paired calculations of single tumor samples and control samples, which greatly increases the cost of analysis. In addition, due to factors such as the difficulty in obtaining adjacent control samples for certain types of cancer patients, improper storage of control samples, or the inability to obtain control samples due to the patient's own reasons, the patient's HRD status cannot be judged, affecting the patient's subsequent medication guidance. Summary of the invention
[0006] The object of the present invention is to provide a method for detecting homologous recombination defects in a single tumor sample based on high-throughput sequencing, wherein the detection method can realize the detection of homologous recombination defects based on a single tumor sample.
[0007] The present invention provides a method for detecting homologous recombination defects in a single tumor sample based on high-throughput sequencing, comprising the following steps:
[0008] Provide BAM files of normal groups;
[0009] Performing SNP detection and analysis based on the normal population BAM file, obtaining SNP information of each sample in the normal population, and merging and homogenizing the SNP information of each sample in the normal population to obtain a SNP database of the normal population;
[0010] Performing copy number variation detection and analysis on the normal population BAM file, and normalizing the obtained normal population copy number variation data to obtain a normal population copy number variation database;
[0011] Perform high-throughput sequencing and quality control on the single tumor sample, compare and filter the obtained single tumor sample data with the human reference genome, and obtain the single tumor sample BAM file;
[0012] Perform SNP detection analysis and copy number variation detection analysis on the single tumor sample BAM file to obtain SNP information of the single tumor sample and copy number variation information of the single tumor sample, respectively;
[0013] Supplementing the SNP database of the normal population with the SNP information of the single tumor sample to obtain simulated somatic cell SNP data;
[0014] Supplementing the copy number variation database of the normal population with the copy number variation information of the single tumor sample to obtain simulated somatic cell copy number variation data;
[0015] The simulated somatic SNP data and the simulated somatic copy number variation data are jointly analyzed to obtain a homologous recombination defect detection result.
[0016] Preferably, the method for obtaining the SNP database of the normal population comprises the following steps:
[0017] Counting the read sequences with a comparison quality greater than 1 in the BAM file of the normal population, and counting the number of bases that are consistent with and inconsistent with the reference genome at the human reference genome comparison coverage site of the read sequence, to form a data file;
[0018] Analyze the data file to obtain SNP information of each sample in the normal population, wherein the SNP information includes the chromosome where the SNP is located, the position of the SNP on the chromosome, the base ref base and the mutant base alt base that the SNP is consistent with the human reference genome, and the sequencing sequence reads support number of the ref and alt bases;
[0019] Combining the SNP information of each sample in the normal population, normalizing the SNP sites of samples from different normal populations, calculating the frequency of the SNP sites after normalization, and obtaining the SNP information of the normal population;
[0020] Calculate the depth information of each site of each sample in the BAM file of the normal population, merge the site depth information of each sample in the normal population, take the average value, and obtain the depth information of the normal population;
[0021] The SNP information of the normal group and the deep information of the normal group are integrated to obtain the SNP database of the normal group.
[0022] Preferably, the step of integrating the SNP information of the normal group and the depth information of the normal group includes: if the depth information site in the depth information of the normal group also exists in the SNP information of the normal group, the depth information site is supplemented with the corresponding SNP information and the normalized ref and alt reads support number and mutation frequency of the SNP information; for the depth information site not detected in the depth information of the normal group, the normalized depth is attributed to the refreads support number, and the alt reads support number and mutation frequency are 0.
[0023] Preferably, the method for obtaining the copy number variation database of the normal population includes any one of the following three methods;
[0024] Method 1: 1) sliding the capture region in the normal population BAM file with a 120 bp window; 2) calculating the normal population sample normalization depth within the 120 bp sliding window to obtain a normal population copy number variation database;
[0025] Method 2: 1) sliding the captured area in the BAM file of the normal population with a 120 bp window; 2) calculating the depth information and log2 value of the depth information in the 120 bp sliding window captured area in step 1) to form a depth information file of the normal population; 3) integrating the depth information files of the normal population to obtain a normal population copy number variation database;
[0026] Method three: 1) sliding the capture region in the normal population BAM file with a 120bp window; 2) constructing a normal population copy number variation database by setting log2 equal to 0 and depth equal to 1 within the 120bp sliding window of the capture region for the human reference genome.
[0027] Preferably, the step of obtaining the simulated somatic SNP variation data includes: according to the position coordinates of the SNP in the tumor single sample SNP information, finding the SNP mutation with the same position coordinates in the SNP database of the normal population, and adding it to the back of the corresponding SNP in the tumor single sample SNP information to obtain the simulated somatic SNP variation data.
[0028] Preferably, the step of obtaining the simulated somatic copy number variation data comprises any one of the following two items:
[0029] The first item: according to the coordinates of the window in the copy number variation information of the single tumor sample, find the depth information of the same position coordinates in the copy number variation database of the normal population, and add it to the back of the corresponding window in the copy number variation information of the single tumor sample; and calculate the log2 value of the normalized depth of the single tumor sample and the normal population in the same sliding window and place it behind the corresponding window to obtain the simulated somatic copy number variation data; the copy number variation database of the normal population is obtained according to method 1 in the above technical solution;
[0030] Item 2: Detect copy number variation in the BAM file of the single tumor sample based on the copy number variation database of the normal population to obtain simulated somatic copy number variation data, wherein the copy number variation database of the normal population is obtained according to method 2 or method 3 in the above technical solution.
[0031] Preferably, in the process of high-throughput sequencing, a DNA library is constructed by capturing SNP sites with equal spacing across the whole genome, with the interval between SNP sites being 50 Kb and the number of SNP sites being 52,000.
[0032] Preferably, the quality control parameters include the following:
[0033] 1) Remove the sequencing sequences in which the bases with base quality less than Q15 account for more than 40%;
[0034] 2) Remove sequencing sequences with more than 5 N bases;
[0035] 3) Slide the 4bp sliding window from the end of the sequencing sequence to the front end. If the quality of the bases in the window is lower than Q20, the bases are removed. Otherwise, the sliding stops.
[0036] 4) Remove the sequencing sequences whose length is less than 15 bp after trimming the low-quality bases in 3).
[0037] Preferably, the human reference genome includes the hg19 reference genome.
[0038] Preferably, obtaining the homologous recombination defect comprises: obtaining the number of heterozygosity loss, large fragment migration and telomeric allele imbalance in a single tumor sample based on the simulated somatic SNP data and the simulated somatic copy number variation data, and calculating the homologous recombination defect according to a predetermined formula (1):
[0039] Homologous recombination defect = number of heterozygous loss + number of large fragment migration + number of telomeric allele imbalance, formula (1).
[0040] The present invention also provides a computer-readable storage medium, on which a computer program or instruction is stored. When the computer program or instruction is executed by a processor, the steps of the detection method described in the above technical solution are implemented.
[0041] The present invention also provides a computer program product, including a computer program or instructions, which implement the steps of the detection method described in the above technical solution when executed by a processor.
[0042] The present invention also provides the use of the detection method described in the above technical solution, the computer-readable storage medium described in the above technical solution, or the computer program product described in the above technical solution in the preparation of a product for guiding tumor drug use.
[0043] Beneficial effects:
[0044] The present invention provides a method for detecting homologous recombination defects in a single tumor sample based on high-throughput sequencing. The present invention first constructs a necessary database through high-throughput sequencing data of a normal population, combines the SNP information and copy number variation information of a single tumor sample, simulates somatic SNP and somatic copy number variation results, and uses the simulated somatic SNP and somatic copy number variation results to jointly analyze to achieve the purpose of calculating the HRD of a single tumor sample. The detection method of the present invention can also calculate the HRD value for single tumor data where a control sample cannot be obtained, and the method is simple and easy to implement, with low cost, and provides a certain evidence basis for determining whether a patient is suitable for drugs including PARP inhibitors and platinum drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required to be used in the embodiments are briefly introduced below.
[0046] Figure 1 This is a flow chart of calculating HRD for a single sample in Example 1;
[0047] Figure 2 This is a correlation result diagram of the HRD values of single and double samples of ICGC database samples in Example 2;
[0048] Figure 3 This is a graph showing the correlation results of the HRD values of real single and double ovarian cancer samples in Example 3. DETAILED DESCRIPTION
[0049] The present invention provides a method for detecting homologous recombination defects in a single tumor sample based on high-throughput sequencing, comprising the following steps:
[0050] Provide BAM files of normal groups;
[0051] Performing SNP detection and analysis based on the normal population BAM file, obtaining SNP information of each sample in the normal population, and merging and homogenizing the SNP information of each sample in the normal population to obtain a SNP database of the normal population;
[0052] Performing copy number variation detection and analysis on the normal population BAM file, and normalizing the obtained normal population copy number variation data to obtain a normal population copy number variation database;
[0053] Perform high-throughput sequencing and quality control on the single tumor sample, compare and filter the obtained single tumor sample data with the human reference genome, and obtain the single tumor sample BAM file;
[0054] Perform SNP detection analysis and copy number variation detection analysis on the single tumor sample BAM file to obtain SNP information of the single tumor sample and copy number variation information of the single tumor sample, respectively;
[0055] Supplementing the SNP database of the normal population with the SNP information of the single tumor sample to obtain simulated somatic cell SNP data;
[0056] Supplementing the copy number variation database of the normal population with the copy number variation information of the single tumor sample to obtain simulated somatic cell copy number variation data;
[0057] The simulated somatic SNP data and the simulated somatic copy number variation data are jointly analyzed to obtain a homologous recombination defect detection result.
[0058] The present invention preferably performs high-throughput sequencing and quality control on normal population samples, compares and filters the obtained normal population sample data with the human reference genome, and obtains a normal population BAM file. In the process of high-throughput sequencing described in the present invention, it is preferred to construct a DNA library by capturing evenly spaced SNP sites in the whole genome, and the interval between SNP sites is preferably 50Kb, and the number of SNP sites is preferably 52,000. The method of capturing evenly spaced SNP sites in the whole genome described in the present invention is preferably hybridized and captured by the whole genome SNP skeleton panel HiSNP UltraPanel, and the whole genome SNP skeleton panel HiSNP UltraPanel has been disclosed in Chinese patent CN202210278698.8. The high-throughput sequencing described in the present invention is preferably second-generation sequencing; the depth of the high-throughput sequencing is preferably 100× or more. The quality control parameters of the present invention preferably include the following items: 1) remove sequencing sequences in which bases with base quality less than Q15 account for more than 40%; 2) remove sequencing sequences with more than 5 N bases; 3) slide the window from the end of the sequencing sequence to the front end with a 4bp sliding window, and cut off when the base quality in the window is lower than Q20, otherwise stop sliding; 4) remove sequencing sequences with a length of less than 15bp after repairing low-quality bases. The quality control parameters of the present invention can ensure the high quality and reliability of the data. The specific process of the quality control of the present invention is not particularly limited, and it can be carried out according to the above parameters using conventional operating procedures. The human reference genome of the present invention is preferably the hg19 reference genome. The present invention preferably marks duplications on the data file after comparison and corrects the base quality through the filtering. The present invention does not specifically limit the software used for the quality control, comparison and filtering, and the conventional quality control, comparison and filtering software in the art can be used.
[0059] The normal population samples described in the present invention preferably include non-tumor samples, and further preferably include but are not limited to normal tissue and / or blood samples of tumor patients and tissue and / or blood samples of normal persons.
[0060] After obtaining the normal population BAM file, the present invention performs SNP detection and analysis based on the normal population BAM file, counts the SNP information of each sample in the normal population, and merges and normalizes them to obtain a SNP database of the normal population.
[0061] The specific construction method of the SNP database of the normal population described in the present invention preferably includes: counting the reads sequences with a comparison quality greater than 1 in the BAM file of the normal population, and counting the number of bases that are consistent with the reference genome and the number of bases that are inconsistent with the reference genome under the human reference genome comparison coverage site of the reads sequence to form a data file; analyzing the data file to obtain the SNP information of each sample in the normal population, the SNP information includes the chromosome where the SNP is located, the position of the SNP on the chromosome, the base ref base and the mutant base alt base that the SNP is consistent with the human reference genome, and the number of sequencing sequence reads supporting the ref and alt bases; merging the SNP information of each sample in the normal population, normalizing the SNP sites of different normal population samples, calculating the frequency of the SNP site after normalization, and obtaining the SNP information of the normal population; calculating the depth information of each site of each sample in the BAM file of the normal population, and merging the site depth information of each sample in the normal population, taking the average value, and obtaining the depth information of the normal population; integrating the SNP information of the normal population and the depth information of the normal population to obtain the SNP database of the normal population.
[0062] The present invention preferably uses the mpileup module of the samtools software to count the read sequences with a comparison quality greater than 1 in the normal population BAM file, and counts the bases of the read sequences that are consistent with the reference genome and the number of inconsistent bases at the human reference genome comparison coverage sites to form a data file. The present invention does not specifically limit the specific process of the statistics, and the conventional use method of the mpileup module of the samtools software can be used.
[0063] After obtaining the data file, the present invention preferably uses the pileup2snp module of the VarScan software to analyze the base ratio at each comparison site in the data file to obtain the SNP information of each sample in the normal population, wherein the SNP information includes the chromosome where the SNP is located, the position of the SNP on the chromosome, the base ref base and the mutant base alt base that are consistent with the human reference genome of the SNP, and the sequencing sequence reads support number of the ref and alt bases.
[0064] After obtaining the SNP information of each sample in the normal population, the present invention preferably merges the SNP information of each sample in the normal population, normalizes the SNP sites of different normal population samples, calculates the SNP site frequency after normalization, and obtains the SNP information of the normal population. The normalization method of the present invention preferably includes: when the same SNP is detected in multiple samples, summing the reads support numbers of ref and alt of the same SNP site detected in different samples in the normal population, and dividing by the total number of normal population samples for normalization; at the same time, when a SNP is detected in only one sample, directly dividing the reads of ref and alt of the unique SNP site detected in the normal population by the total number of normal population samples for normalization.
[0065] At the same time, the present invention preferably uses the samtools software depth module to calculate the depth information of each site of each sample in the normal population BAM file, and merges the site depth information of each sample in the normal population, takes the depth average, and obtains the depth information of the normal population. The present invention has no special limitation on the process of obtaining the depth information of the normal population using the samtools software depth module, and the conventional operation in the art can be used.
[0066] After obtaining the depth information of the normal population, the present invention preferably integrates the SNP information of the normal population and the depth information of the normal population to obtain the SNP database of the normal population. The integration step of the present invention preferably includes: if the depth information site in the depth information of the normal population also exists in the SNP information of the normal population, the corresponding SNP information and the normalized ref and alt reads support and mutation frequency of the SNP information are supplemented to the depth information site; for the depth information site not detected in the depth information of the normal population, the normalized depth is attributed to the refreads support number, and the alt reads support number and mutation frequency are 0.
[0067] After obtaining the normal population BAM file, the present invention performs copy number variation detection and analysis on the normal population BAM file, and normalizes the obtained normal population copy number variation data to obtain a normal population copy number variation database. The step of constructing the normal population copy number variation database of the present invention preferably includes any one of the following three methods;
[0068] Method 1: 1) sliding the capture region in the normal population BAM file with a 120 bp window; 2) calculating the normal population sample normalization depth within the 120 bp sliding window to obtain a normal population copy number variation database;
[0069] Method 2: 1) sliding the captured area in the BAM file of the normal population with a 120 bp window; 2) calculating the depth information and log2 value of the depth information in the 120 bp sliding window captured area in step 1) to form a depth information file of the normal population; 3) integrating the depth information files of the normal population to obtain a normal population copy number variation database;
[0070] Method three: 1) sliding the capture region with a 120bp window; 2) the log2 of the human reference genome within the 120bp sliding window of the capture region is equal to 0, and the depth is equal to 1, and a normal population copy number variation database is constructed.
[0071] In method 1 described in the present invention, the step of calculating the normalized depth in step 2) of the present invention preferably includes: counting the depth mean of the depth information of the normal population in the 120bp sliding window capture area in step 1), and dividing it by the average depth, that is, the mean of the depth information of the normal population, and the obtained normalized depth of the normal population in the 120bp sliding window capture area is the normal copy number variation database.
[0072] In method 2 of the present invention, the present invention preferably uses the coverage module of cnvkit software to calculate the depth information and log2 value of the depth information within the 120bp sliding window capture area in step 2). The present invention preferably uses the reference module of cnvkit software to perform the integration described in step 3).
[0073] In the third method described in the present invention, the present invention preferably uses the reference module of cnvkit software to perform the calculation described in step 2).
[0074] While constructing the SNP database of the normal population and the copy number variation database of the normal population, the present invention performs high-throughput sequencing and quality control on the single tumor sample, compares and filters the obtained single tumor sample data with the human reference genome, and obtains the single tumor sample BAM file. The process of high-throughput sequencing, quality control, comparison and filtering of the single tumor sample described in the present invention is preferably the same as the corresponding process of the normal population sample described in the above technical solution, and will not be repeated; the depth of the high-throughput sequencing is preferably 500× or more.
[0075] After obtaining the single tumor sample BAM file, the present invention performs SNP detection analysis and copy number variation detection analysis on the single tumor sample BAM file, respectively, to obtain the single tumor sample SNP information and single tumor sample copy number variation information, respectively. The present invention preferably uses the pileup2snp module of the VarScan software to perform the SNP detection analysis. The copy number variation analysis of the present invention preferably includes: using the depth of the samtools software to calculate the depth of each site of the single tumor sample in the capture area, and calculating the overall average depth in the capture area; sliding the capture area with a 120bp window, calculating the average depth in the 120bp sliding window; dividing the average depth in the 120bp sliding window by the overall average depth in the capture area for normalization, and obtaining the single tumor sample copy number variation information.
[0076] After obtaining the tumor single sample SNP information, the tumor single sample copy number variation information, the SNP database of the normal population and the copy number variation database of the normal population, the present invention supplements the SNP database of the normal population in the tumor single sample SNP information to obtain simulated somatic cell SNP data; at the same time, the present invention supplements the copy number variation database of the normal population in the tumor single sample copy number variation information to obtain simulated somatic cell copy number variation data.
[0077] The method for obtaining the simulated somatic SNP data of the present invention preferably includes: based on the position coordinates of the SNP in the tumor single sample SNP information, finding the SNP mutation with the same position coordinates in the SNP database of the normal population, and adding it to the back of the corresponding SNP in the tumor single sample SNP information to obtain the simulated somatic SNP variation data.
[0078] The step of obtaining the simulated somatic copy number variation data of the present invention preferably includes: including any one of the following two items: the first item: according to the coordinates of the window in the tumor single sample copy number variation information, find the depth information of the same position coordinates in the copy number variation database of the normal population, and add it to the back of the corresponding window in the tumor single sample copy number variation information; and calculate the log2 value of the normalized depth of the tumor single sample and the normal population in the same sliding window and place it behind the corresponding window to obtain the simulated somatic copy number variation data; the copy number variation database of the normal population is obtained according to the method 1 described in the above technical solution;
[0079] Item 2: Detect copy number variation in the BAM file of the single tumor sample based on the copy number variation database of the normal population to obtain simulated somatic copy number variation data, wherein the copy number variation database of the normal population is obtained according to method 2 or method 3 in the above technical solution.
[0080] In the second item of the present invention, the present invention preferably uses the batch module of cnvkit software to detect copy number variation.
[0081] After obtaining the simulated somatic copy number variation data and the simulated somatic SNP data, the present invention jointly analyzes the simulated somatic SNP data and the simulated somatic copy number variation data to obtain a homologous recombination defect detection result. Specifically, the acquisition of the homologous recombination defect in the present invention preferably includes: obtaining the number of heterozygosity loss, large fragment migration and telomeric allele imbalance in a single tumor sample based on the simulated somatic SNP data and the simulated somatic copy number variation data, and calculating the homologous recombination defect according to a predetermined formula (1):
[0082] Homologous recombination defect = number of heterozygous loss + number of large fragment migration + number of telomeric allele imbalance, formula (1).
[0083] The present invention also provides a computer-readable storage medium, on which a computer program or instruction is stored. When the computer program or instruction is executed by a processor, the steps of the detection method described in the above technical solution are implemented.
[0084] The present invention also provides a computer program product, including a computer program or instructions, which implement the steps of the detection method described in the above technical solution when executed by a processor.
[0085] The detection method of the present invention can also calculate the HRD value for single tumor data when control samples cannot be obtained. The method is simple, easy and low-cost, and provides a certain evidence basis for determining whether a patient is suitable for drugs including PARP inhibitors and platinum drugs.
[0086] Based on the above advantages, the present invention also provides the use of the detection method described in the above technical solution, the computer-readable storage medium described in the above technical solution, or the computer program product described in the above technical solution in the preparation of a product for guiding tumor medication. The tumor medication described in the present invention preferably includes but is not limited to platinum drugs and / or PARP inhibitors.
[0087] In order to further illustrate the present invention, the technical solution provided by the present invention is described in detail below in conjunction with the accompanying drawings and embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0088] Example 1
[0089] A method for calculating homologous recombination defect (HRD) in a single human tumor sample based on next-generation sequencing, the steps are as follows, and the flowchart is as follows Figure 1 Shown
[0090] 1. Extract DNA from single tumor samples and normal population samples respectively, and use the whole genome SNP backbone panel HiSNP Ultra Panel v1.0 (the panel is disclosed in Chinese patent CN202210278698.8) for hybridization capture library construction;
[0091] 2. Perform second-generation NGS sequencing on the hybridization capture libraries respectively;
[0092] 3. Perform quality control on the data from the second-generation NGS sequencing machine, remove the sequencing sequences with bases with base quality less than Q15 accounting for more than 40%, remove the sequencing sequences with more than 5 N bases, use a 4bp sliding window to slide from the end of the sequencing sequence to the front end, if the average quality of the bases in the window is lower than Q20, cut it off, otherwise stop sliding, remove the sequencing sequences with a length of less than 15bp after trimming the low-quality bases, to ensure the high quality and reliability of the data;
[0093] 4. The high-quality data of the tumor single sample and the normal group sample after quality control were respectively aligned to the human reference genome hg19, and the repeated sequences were marked and the base quality was recalibrated to obtain the BAM file for subsequent analysis;
[0094] 5. Construction of normal population mutation SNP database:
[0095] (1) The mpileup module of samtools (version: 1.9) software was used to analyze the BAM files of normal population samples, and the read sequences aligned to the genome with an alignment quality MQ greater than 1 were counted. The number of consistent and inconsistent bases between these sequences and the genome at the genome alignment coverage sites was counted;
[0096] (2) Using the pileup2snp module of the VarScan (version: 2.4.3) software, analyze the base ratio at each alignment site in the file obtained in (1), and then obtain the SNP information of each normal population sample: the chromosome where the SNP is located, the position of the SNP on the chromosome, the ref base and the mutant base alt base of the SNP that are consistent with the genome, the number of sequencing reads supporting the ref and alt bases, and the mutation frequency calculated based on the ref and alt reads;
[0097] (3) Merge the SNPs detected in all normal samples, sum the support numbers of ref and alt reads of the same SNP site detected in different samples, and divide it by the total number of samples for normalization. Directly divide the support numbers of ref and alt reads of the only SNP site detected in the sample by the total number of samples for normalization, so as to obtain the SNP information of the normal population;
[0098] (4) Using the depth module of the samtools software, the depth information of each site within the capture panel was calculated for the BAM files of the normal population samples, and then the site depth information of all normal samples was merged and divided by the number of samples to obtain the depth information of the normal population;
[0099] (5) The SNP information of the normal population and the deep information of the normal population are integrated. If the deep information site also exists in the SNP information, the corresponding SNP information and the normalized reads support numbers of ref and alt are supplemented for the deep information site. For the deep information site not detected in the SNP information, the normalized depth is attributed to the refreads support number, and the alt reads support number and mutation frequency are 0, thereby obtaining the SNP information database of the normal population.
[0100] 6. There are three methods for constructing a normal population copy number variation database:
[0101] Method 1:
[0102] (1) First, slide the capture panel capture area using a 120 bp window;
[0103] (2) Calculate the average depth of the depth information of the normal group obtained in step 5;
[0104] (3) Calculate the mean depth of the depth information of the normal population in step 5 within the 120 bp sliding window capture area, and divide it by the average depth to obtain the normalized depth of the normal population within the 120 bp sliding window capture area;
[0105] Method 2:
[0106] (1) First, slide the capture panel capture area using a 120 bp window;
[0107] (2) For the BAM files of normal population samples, the coverage module of cnvkit (version: 0.9.9) software was used to calculate the depth information and log2 value within the 120 bp capture region;
[0108] (3) The reference module of cnvkit software integrates the deep information files of all normal samples to generate a normal population copy number variation database.
[0109] Method 3:
[0110] (1) First, slide the capture panel capture area using a 120 bp window;
[0111] (2) The reference module of cnvkit software calculates the copy number variation database of the normal population within the 120bp sliding window of the reference genome.
[0112] 7. Construct simulated somatic SNP results for a single tumor sample
[0113] (1) Use the mpileup module of the samtools software to analyze the BAM files of single tumor samples, count the sequences in the BAM files with a quality greater than 1, and calculate the base changes at the coverage sites on the genome;
[0114] (2) Using the pileup2snp module of the VarScan software, analyze the file obtained in (1) to obtain the SNP information of the single tumor sample;
[0115] (3) The SNP sites in the single tumor sample are supplemented with the SNP database data of the normal population to obtain a simulated somatic cell SNP file;
[0116] Specifically, the supplementation means: according to the position coordinates of the tumor single sample SNP, the mutation with the same position coordinates is found in the SNP database of the normal population, and supplemented after the tumor single sample SNP information, that is, a row of SNPs has both the ref and alt reads information of the tumor single sample and the ref and alt reads information of the normal population.
[0117] 8. Construct simulated somatic copy number variation results for single tumor samples
[0118] Method 1:
[0119] (1) Use the depth of samtools software to calculate the depth of each site in the capture area of a single tumor sample;
[0120] (2) Calculate the overall average depth of a single tumor sample within the capture area;
[0121] (3) Slide the capture panel capture area with a 120 bp window, calculate the average depth within the 120 bp sliding window, and divide it by the overall average depth of the tumor single sample for normalization;
[0122] (4) Integrate the normal population copy number variation database obtained by method 1 in step 6 with the copy number variation information of the single tumor sample, and calculate the log2 value of the normalized depth of the single tumor sample and the normal population in the same sliding window to obtain the simulated somatic copy number variation information;
[0123] Specifically, the integration means: according to the coordinates of the single tumor sample window, find the depth information of the same position coordinates in the normal population copy number variation database, add it to the window of the single tumor sample, and at the same time take the log2 of the ratio of the normalized depth of the tumor sample and the normal population, and put it behind this window information.
[0124] Method 2: Use the batch module of cnvkit software to detect copy number variation in the BAM file of a single tumor sample based on the normal population copy number variation database obtained in method 2 in step 6 to obtain simulated somatic copy number variation information;
[0125] Method 3: Using the batch module of cnvkit software, based on the normal population copy number variation database obtained in method 3 in step 6, the BAM file of the tumor single sample is tested for copy number variation to obtain simulated somatic copy number variation information;
[0126] 9. Calculate HRD: Based on the somatic mutation SNP and somatic copy number variation information simulated in the single tumor sample, use sequenza (version: 2.1.2) and ScarHRD (version: 0) for analysis to obtain the number of heterozygosity loss, large fragment migration, and telomeric allele imbalance in the single tumor sample. The sum of the three numbers is the homologous recombination defect HRD value.
[0127] Example 2
[0128] This example uses WGS BAM data of 70 paired ovarian cancer tumors and controls downloaded from the International Cancer Genome Consortium (ICGC) database, extracts data within the HiSNP Ultra Panel v1.0 capture region from the WGS BAM file, and simulates Hi SNP Ultra Panel v1.0 capture hybridization data.
[0129] Paired analysis of HRD: For the BAM data captured by simulated HiSNPs of paired tumors and controls, the mpileup module of samtools software was used to count the read sequences with alignment quality greater than 1 and the changes in bases at the genomic alignment position. Then, the somatic module of VarScan software was used to jointly analyze the output results of samtools mpileup of tumors and controls to obtain the somatic mutation SNP results. The copynumber module of VarScan software obtained the copy number variation results based on the output results of samtools mpileup of tumors and controls. Sequenza and scarHRD were used to analyze somatic mutation SNPs and copy number variation, and the purity and HRD values of paired calculated tumor samples were obtained.
[0130] The steps in Example 1 were used to perform single sample HRD analysis: a SNP database and a copy number variation database of a normal population were constructed for the control sample in the 70 paired samples, and then the purity and HRD values of the tumor single samples in the 70 paired samples were analyzed using the SNP of the normal population and the copy number variation database constructed by the three methods, wherein the three methods for constructing copy number variation were:
[0131] Method 1: Normal population copy number variation database was generated by normalizing the depth of normal population within the 120bp sliding window capture region;
[0132] Method 2: The cnvkit software calculates and integrates the 120bp sliding window capture region depth information file for all normal samples to generate a normal population copy number variation database;
[0133] Method 3: The cnvkit software calculates the genome copy number variation database within the 120bp sliding window of the hg19 reference genome.
[0134] The correlation between paired and single sample purity of HiSNP simulation data of 70 ICGC samples is shown in Figure 2 In (a), M1 represents method 1, M2 represents method 2, and M3 represents method 3. Figure 2 (a) shows the correlation R between the purity calculated by single sample and the purity calculated by paired sample under three different methods of constructing copy number variation database 2 They are all greater than 0.85, indicating that the purity calculated by a single sample can be used for data filtering and screening.
[0135] Studies have shown that because samples with low tumor purity contain too many normal cells, the calculated HRD value deviates greatly from the actual tumor HRD status. Therefore, it is generally believed that when the tumor purity is greater than 0.3, the calculated HRD value is more reliable. After removing samples with HRD less than or equal to 0.3 based on the purity calculated by a single sample, the consistency of the HRD values calculated by a single sample and a paired sample is shown in Figure 2. Figure 2 (b) Correlation R under three different methods of constructing copy number variation database 2 Basically, they are all at 0.93. This embodiment shows that the HRD value of a single sample calculated by this method is highly consistent with the HRD value calculated for paired samples.
[0136] Example 3
[0137] The HRD of real tumor samples was detected and calculated using the method disclosed in Example 1. The specific steps are as follows:
[0138] DNA was extracted from 81 ovarian cancer real tumor FFPE samples and 84 adjacent FFPE samples, and then hybridized and captured and sequenced using HiSNP UltraPanel v1.0. The sequencing data was compared with the genome after quality control. Among them, 84 normal control samples were used to construct a population SNP database and a copy number variation database. The three detection methods of the copy number variation database are as follows:
[0139] Method 1: Normal population copy number variation database was generated by normalizing the depth of normal population within the 120bp sliding window capture region;
[0140] Method 2: The cnvkit software calculates and integrates the 120bp sliding window capture region depth information file for all normal samples to generate a normal population copy number variation database;
[0141] Method 3: The cnvkit software calculates the genome copy number variation database within the 120bp sliding window of the hg19 reference genome.
[0142] Paired analysis of HRD: 81 real ovarian cancer tumors and corresponding control samples were analyzed using the samtools mpileup module of the software to count the read sequences with alignment quality greater than 1 and the changes in bases at the genomic alignment position. Then, the somatic module of the software VarScan was used to jointly analyze the output results of the samtools mpileup of the tumor and control to obtain the somatic mutation SNP results. The copynumber module of the software VarScan was used to obtain the copy number variation results based on the output results of the samtools mpileup of the tumor and control. Sequenza and scarHRD were used to analyze somatic mutation SNPs and copy number variation, and the purity and HRD values of the tumor samples calculated by pairing were obtained.
[0143] Single sample analysis HRD: The single sample HRD values were calculated for 81 real ovarian cancer tumor samples using the SNP and copy number variation database of 84 real control samples and the SNP and copy number variation database constructed using the simulated HiSNP data of 70 ICGC normal samples in Example 1.
[0144] A SNP and copy number variation database was constructed from 84 real ovarian cancer control samples. Single-sample HRD was calculated for 81 real ovarian cancer tumor samples. After screening and removing samples with purity less than 0.3 calculated under single sample, the correlation with the HRD value calculated for paired samples is shown in Figure 2. Figure 3 In (a), M1 represents method 1, M2 represents method 2, and M3 represents method 3. Figure 3 In (a), we can see the correlation R between the HRD value calculated for a single sample and the HRD value for paired samples under three different methods of constructing a copy number variation database. 2 All of them are greater than 0.9, showing a high degree of consistency.
[0145] When the control sample as the group is replaced with the simulated data of ICGC, the correlation between the HRD calculated by the single sample and the HRD calculated by the paired sample is shown in Figure 3 (b), where M1 represents method 1, M2 represents method 2, and M3 represents method 3. The figure shows the correlation R between the HRD value calculated for a single sample and the HRD value for paired samples under three different copy number variation databases and different control populations. 2 It can still be maintained at 0.89. This example shows that the single sample HRD and the double sample HRD calculated by the method of calculating HRD of a single tumor sample are highly correlated and consistent, and even if the reference SNP and copy number variation database constructed by different normal populations, the results are still consistent, indicating that the single sample HRD calculation can be used to replace the paired sample HRD.
[0146] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. A method for detecting homologous recombination defects in a single tumor sample based on high-throughput sequencing, characterized in that: The steps include: Provide BAM files of normal groups; Performing SNP detection and analysis based on the normal population BAM file, obtaining SNP information of each sample in the normal population, and merging and homogenizing the SNP information of each sample in the normal population to obtain a SNP database of the normal population; Performing copy number variation detection and analysis on the normal population BAM file, and normalizing the obtained normal population copy number variation data to obtain a normal population copy number variation database; Perform high-throughput sequencing and quality control on the single tumor sample, compare and filter the obtained single tumor sample data with the human reference genome, and obtain the single tumor sample BAM file; Perform SNP detection analysis and copy number variation detection analysis on the single tumor sample BAM file to obtain SNP information of the single tumor sample and copy number variation information of the single tumor sample, respectively; Supplementing the SNP database of the normal population with the SNP information of the single tumor sample to obtain simulated somatic cell SNP data; Supplementing the copy number variation database of the normal population with the copy number variation information of the single tumor sample to obtain simulated somatic cell copy number variation data; The simulated somatic SNP data and the simulated somatic copy number variation data are jointly analyzed to obtain a homologous recombination defect detection result.
2. The detection method according to claim 1, characterized in that: The method for obtaining the SNP database of the normal population comprises the following steps: Counting the read sequences with a comparison quality greater than 1 in the BAM file of the normal population, and counting the number of bases that are consistent with and inconsistent with the reference genome at the human reference genome comparison coverage site of the read sequence, to form a data file; Analyze the data file to obtain SNP information of each sample in the normal population, wherein the SNP information includes the chromosome where the SNP is located, the position of the SNP on the chromosome, the base ref base and the mutant base alt base that the SNP is consistent with the human reference genome, and the sequencing sequence reads support number of the ref and alt bases; Combining the SNP information of each sample in the normal population, normalizing the SNP sites of samples from different normal populations, calculating the frequency of the SNP sites after normalization, and obtaining the SNP information of the normal population; Calculate the depth information of each site of each sample in the BAM file of the normal population, merge the site depth information of each sample in the normal population, take the average value, and obtain the depth information of the normal population; The SNP information of the normal group and the deep information of the normal group are integrated to obtain the SNP database of the normal group.
3. The detection method according to claim 2, characterized in that: The step of integrating the SNP information of the normal group and the depth information of the normal group includes: if the depth information site in the depth information of the normal group also exists in the SNP information of the normal group, supplementing the corresponding SNP information and the normalized reads support number and mutation frequency of ref and alt of the SNP information to the depth information site; For deep information sites that are not detected in the deep information of the normal population, the normalized depth is attributed to the refreads support number, and the alt reads support number and mutation frequency are 0.
4. The detection method according to claim 1, characterized in that: The method for obtaining the copy number variation database of the normal population includes any one of the following three methods; Method 1: 1) sliding the capture region in the BAM file of the normal population with a 120 bp window; 2) Calculate the normal population sample normalization depth within the 120bp sliding window to obtain the normal population copy number variation database; Method 2: 1) sliding the captured area in the BAM file of the normal population with a 120 bp window; 2) calculating the depth information and log2 value of the depth information in the 120 bp sliding window captured area in step 1) to form a depth information file of the normal population; 3) Integrating the deep information files of the normal population to obtain a normal population copy number variation database; Method 3: 1) Slide the capture region with a 120 bp window; 2) The human reference genome has a log2 of 0 and a depth of 1 within the 120bp sliding window of the capture region, and a normal population copy number variation database is constructed.
5. The detection method according to any one of claims 1 to 3, characterized in that: The step of obtaining the simulated somatic SNP data includes: according to the position coordinates of the SNP in the tumor single sample SNP information, finding the SNP mutation with the same position coordinates in the SNP database of the normal population, and adding it to the back of the corresponding SNP in the tumor single sample SNP information to obtain the simulated somatic SNP variation data.
6. The detection method according to claim 4, characterized in that: The step of obtaining the simulated somatic copy number variation data includes any one of the following two items: Item 1: according to the coordinates of the window in the copy number variation information of the single tumor sample, find the depth information of the same position coordinates in the copy number variation database of the normal population, and add it to the back of the corresponding window in the copy number variation information of the single tumor sample; and calculate the log2 value of the normalized depth of the single tumor sample and the normal population in the same sliding window and place it behind the corresponding window to obtain the simulated somatic copy number variation data; the copy number variation database of the normal population is obtained according to method 1 in claim 4; Item 2: Detect copy number variation in the BAM file of the single tumor sample based on the copy number variation database of the normal population to obtain simulated somatic copy number variation data, wherein the copy number variation database of the normal population is obtained according to method 2 or method 3 in claim 4.
7. The detection method according to claim 1, characterized in that: In the process of high-throughput sequencing, a DNA library was constructed by capturing SNP sites with equal spacing across the whole genome, with the interval between SNP sites being 50 Kb and the number of SNP sites being 52,000.
8. The detection method according to claim 1, characterized in that: The quality control parameters include the following: 1) Remove the sequencing sequences in which the bases with base quality less than Q15 account for more than 40%; 2) Remove sequencing sequences with more than 5 N bases; 3) Slide the 4bp sliding window from the end of the sequencing sequence to the front end. If the quality of the bases in the window is lower than Q20, the bases are removed. Otherwise, the sliding stops. 4) Remove the sequencing sequences whose length is less than 15 bp after trimming the low-quality bases in 3).
9. The detection method according to claim 1, characterized in that: The human reference genome includes the hg19 reference genome.
10. The detection method according to claim 1, characterized in that: The homologous recombination defect is obtained by analyzing the number of heterozygosity loss, large fragment migration and telomeric allele imbalance in a single tumor sample based on the simulated somatic cell SNP data and the simulated somatic cell copy number variation data, and calculating the homologous recombination defect according to a predetermined formula (1): Homologous recombination defect = number of heterozygous loss + number of large fragment migration + number of telomeric allele imbalance, formula (1).
11. A computer-readable storage medium having a computer program or instruction stored thereon, characterized in that: When the computer program or instruction is executed by a processor, the steps of any detection method of claims 1-10 are implemented.
12. A computer program product comprising a computer program or instructions, characterized in that When the computer program or instruction is executed by a processor, the steps of the detection method according to any one of claims 1 to 10 are implemented.
13. Use of the detection method according to any one of claims 1 to 10, the computer-readable storage medium according to claim 11, or the computer program product according to claim 12 in the preparation of a product for guiding tumor medication.
Citation Information
Patent Citations
Single-sample whole-genome allele specific copy number variation prediction method
CN112802548A
NGS platform-based homologous recombination defect detection method and quality control system
CN113658638A
Homologous recombination defect gene analysis method
CN114300053A
Method for Providing Information of Genetic Scar Prediction Based on Copy Number Variation in Off-target Region of Cancer Related Genes and Homologous Recombination Repair Genes
KR102547885B1
Homologous recombination repair deficiency detection
US20220025468A1
